|本期目录/Table of Contents|

[1]严一杰,张军,王硕,等.125I粒子植入的靶区勾画对一线治疗后局部进展的非小细胞肺癌治疗效果影响[J].天津医科大学学报,2021,27(06):586-590.
　YAN Yi-jie,ZHANG Jun,WANG Shuo,et al.Effect of target delineation of 125I seed implantation on the treatment of locally advanced non-small cell lung cancer after first-line therapy[J].Journal of Tianjin Medical University,2021,27(06):586-590.
点击复制

125I粒子植入的靶区勾画对一线治疗后局部进展的非小细胞肺癌治疗效果影响(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
27卷
期数:
2021年06期
页码:
586-590
栏目:
肿瘤性疾病专题
出版日期:
2021-11-15

文章信息/Info

Title:
Effect of target delineation of 125I seed implantation on the treatment of locally advanced non-small cell lung cancer after first-line therapy
文章编号:
1006-8147（2021）06-0586-05
作者:
严一杰; 张军; 王硕; 孟繁杰; 王斌; 关志宇
（天津医科大学第二医院胸外科，天津300211）
Author(s):
YAN Yi-jie; ZHANG Jun; WANG Shuo; MENG Fan-jie; WANG Bin; GUAN Zhi-yu
（Department of Thoracic Surgery，The Second Hospital，Tianjin Medical University，Tianjin 300211，China）
关键词:
非小细胞肺癌; 125I放射性粒子植入; 靶区勾划; 肿瘤复发
Keywords:
non-small cell lung cancer; 125I radioactive seed implantation; target delineation; tumor recurrence
分类号:
R734.2
DOI:
-
文献标志码:
A
摘要:
目的：探讨一线放化疗后局部进展非小细胞肺癌（NSCLC）125I粒子植入术中靶区勾画方式对肿瘤治疗效果的影响。方法 ：选取2017年10月—2019年12月一线治疗后局部进展NSCLC患者70例，分为两组，每组35例，对照组沿胸部CT肺窗肿瘤边缘直接划定靶区，观察组以胸部CT肺窗肿瘤外边缘7 mm为靶区。比较两组植入前和植入后6个月的胸部CT表现，并在1年随访中比较两组术后不良反应发生率、客观缓解率、原位肿瘤复发率和无进展生存期。结果： 两组患者均顺利完成植入，不良反应发生率比较差异无统计学意义（20.0% vs. 17.1%，P=0.759），客观缓解率比较差异无统计学意义（91.43% vs. 85.71%，P=0.710），观察组原位复发率低于对照组（5.71% vs. 25.71%，P=0.022）。随访1年，中位无进展生存期高于对照组（12.58个月 vs. 11.36个月，P=0.037）。结论 ：胸部CT肺窗肿瘤外缘7 mm勾画靶区，行125I粒子植入可减少肿瘤原位复发，延长生存期。
Abstract:
Objective： To investigate the effect of target delineation during 125I seed implantation on tumor recurrence in patients with locally advanced non-small cell lung cancer after first-line treatment. Methods: A total of 70 patients with locally advanced non-small cell lung cancer after first-line treatment in our hospital from October 2017 to December 2019 were divided into two groups: control group（n=35） and observation group（n=35）. The target area was directly delineated along the edge of chest CT lung window tumor in the control group and 7 mm on the outer edge of chest CT lung window tumor in the observation group. The chest CT findings before and 6 months after implantation were compared between the two groups，and the incidence of postoperative adverse reactions，objective remission rate，tumor recurrence rate in situ and progression free survival were compared between the two groups during 1-year follow-up. Results: The two groups were successfully implanted，the incidence of adverse reactions had no significant difference（20.0% vs. 17.1%，P= 0.759），the objective remission rate had no significant difference（91.43% vs. 85.71%，P=0.710），the in situ recurrence rate of the observation group was lower than that of the control group（5.71% vs. 25.71%，P=0.022）. One year follow-up showed that the median progression free survival of the observation group was higher than that of the control group（12.58 months vs. 11.36 months，P = 0.037）. Conclusion: The target area is delineated 7 mm from the outer edge of chest CT lung window tumor，and implanted with 125I seeds can reduce tumor recurrence in situ and prolong the survival time.

参考文献/References:

[1] WANG J，CHAI S，ZHENG G，et al. Chinese expert consensus on radioactive 125I seeds interstitial implantation brachy therapy for pancreatic cancer[J]. J Cancer Res Ther，2018，14（1）：12
[2] LI H，DUAN Z，ZHAO C，et al. Combination of brachytherapy with jodine-125 seeds and systemic chemotherapy versus systemic chemotherapy alone for synchronous extracranial oligometastatic non-small cell lung cancer[J]. Cancer Manag Res，2020，12： 8209
[3] NESTLE U，SCHIMEK-JASCH T，KREMP S，et al. Imaging-based target volume reduction in Chemoradiotherapy for locally advanced non-small-cell lung cancer （PET-Plan）： a multicentre，open-label，randomised，controlled trial[J]. Lancet Oncol，2020，21：581
[4] THEELEN WSME，CHEN D，VERMA V，et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer： a pooled analysis of two randomised trials[J]. Lancet Respir Med，2021，9：467
[5] GRILLS I S，FITCH D L，GOLDSTEIN N S，et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma：defining clinical target volume for radiotherapy[J]. Int J Radiat Oncol Biol Phys，2007，69（2）：334
[6] 付亮，王宏亮，赵钰. 周围型肺癌在多层螺旋CT诊断中的影像学表现与术后病理学诊断的一致性分析[J]. 中国CT和MRI杂志，2020，18（4）：43
[7] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1）[J]. Eur J Cancer，2009，45（2）：228
[8] 李长平，胡良平.定性资料的数据结构与分析方法概述[J].四川精神卫生，2019，32（4）：289
[9] COU?譙AGO F，DE LA PINTA C，GONZALO S，et al. GOECP/SEOR radiotherapy guidelines for small-cell lung cancer[J]. World J Clin Oncol，2021，12（3）：115
[10] 王一青，朱林海，林旭，等. CT引导下125I粒子植入术对晚期肺转移癌的治疗作用［J］. 中国肺癌杂志，2020，23（6）：424
[11] CHEN Y，JIANG Y，JI Z，et al. Dosimetry，efficacy，and safety of three-dimensional printing noncoplanar template-assisted and CT-guided 125I seed implantation for recurrent retroperitoneal lymphatic metastasis after external beam radiotherapy[J]. Brachytherapy，2020，19（3）：380
[12] O′DONNELL J S，TENG MWL，SMYTH M J. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol，2019，16（3）：151
[13] NORONHA V，PATIL V M，JOSHI A，et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in-mutated lung cancer[J]. J Clin Oncol，2020，38，124
[14] DAI F，WANG J，AN H，et al. Therapy of 125I particles implantation inhibited the local growth of advanced non-small cell lung cancer： a retrospective clinical study[J]. Am J Transl Res，2019，11（6）：3737
[15] 王喆，王若雨. 放射性粒子治疗实体恶性肿瘤的进展[J]. 大连医科大学学报，2020，42（2）：97
[16] WARD Z J，SCOTT A M，HRICAK H，et al. Global costs，health benefits，and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers： a simulation-based analysis[J]. Lancet Oncol，2021，22（3）：341

相似文献/References:

[1]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(03):51.
　LIANG Shao-ping,WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(06):51.
[2]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(01):51.
　LIANG Shao-ping WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(06):51.
[3]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(06):417.
[4]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(06):417.
[5]黄晓莹.MRI与CT在非小细胞肺癌淋巴结转移诊断中的应用价值比较[J].天津医科大学学报,2017,23(06):542.
　HUANG Xiao-ying.Application value of MRI and CT in the diagnosis of lymph node metastasis of non-small cell lung cancer[J].Journal of Tianjin Medical University,2017,23(06):542.
[6]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.
[7]王红军,贾金广,朱婉凌,等.CXCL-14在非小细胞肺癌中的表达水平及临床意义[J].天津医科大学学报,2021,27(02):112.
　WANG Hong-jun,JIA Jin-guang,ZHU Wan-ling,et al.The expression level and clinical significance of CXCL-14 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2021,27(06):112.
[8]张萌,孟昭婷,张翠翠,等.Super-ARMS法检测EGFR突变在NSCLC的临床应用[J].天津医科大学学报,2021,27(02):185.
　ZHANG Meng,MENG Zhao-ting,ZHANG Cui-cui,et al.Clinical application of EGFR mutation in NSCLC detect by the way of Super-arms[J].Journal of Tianjin Medical University,2021,27(06):185.
[9]陈嫱,英硕,李冠华,等.非小细胞肺癌M1期患者的危险、预后因素和转移特征：一项基于SEER数据库的研究[J].天津医科大学学报,2022,28(01):27.
　CHEN Qiang,YING Shuo,LI Guan-hua,et al.The risk，prognostic factors and metastatic features for patients with M1 stage of non-small cell lung cancer: a SEER-based study[J].Journal of Tianjin Medical University,2022,28(06):27.

备注/Memo

备注/Memo:
作者简介 严一杰（1990-），男，医师,硕士，研究方向：肺癌的综合治疗；通信作者：关志宇，E-mail：guanzy69@163.com。
更新日期/Last Update: 2021-11-15